Celltrion Inc (068270) fair value: what the stock is really worth
We calculate from audited financials what Celltrion Inc is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Celltrion Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 18, 2026.
How to read this chart
60‑month range 130,526 KRW – 290,268 KRW · fair‑value band 52,383 KRW – 109,408 KRW · the 181,400 KRW price screens above the 74,519 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 18, 2026.
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products.
Show more
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and non-small cell lung cancer; Omlyclo for Asthma and urticaria; Eydenzelt for diabetic macular edema and wet age-related macular degeneration; Steqeyma for psoriasis and inflammatory bowel disease; Stoboclo/Osenvelt for osteoporosis; Avtozma for rheumatoid arthritis and active systemic juvenile idiopathic arthritis; Zymfentra for inflammatory bowel disease; and Regkirona for COVID-19, as well as CT-G07 for HIV/AIDS and Donerion Patch for Alzheimer's dementia symptoms. The company is also developing biosimilars, which are in Phase 3 clinical trials include CT-P44 for multiple myeloma, CT-P51 for melanoma and lung cancer, CT-P53 for multiple sclerosis, and CT-P55 for psoriasis, as well as CT-G20 for hypertrophic cardiomyopathy. It distributes its products in approximately 100 countries, including the United States and Europe. The company was founded in 2002 and is headquartered in Incheon, South Korea.
Stock analysis
Celltrion Inc (068270) currently trades at 181,400 KRW, while our model-based Fair Value estimate is 74,519 KRW, implying the stock looks roughly 143.4% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 135,611 KRW per share, and 1 of the 26 models we run sit above the 181,400 KRW price.
Bear case: the Dividend Discount group reads lowest at 11,534 KRW, and 25 of the 26 models stay below the price. Evidence for this calculation is medium.
Scenario range: 52,383 KRW (bear) to 109,408 KRW (bull), the price of 181,400 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Celltrion Inc reported revenue of 4.2T KRW in FY2025 versus 1.9T KRW in FY2021, a compound +21.5%/yr. Reported net income was 1.0T KRW in FY2025, compounding +15.5%/yr from FY2021.
Key figures
Market cap 39.7T KRW (≈ $27.8B) · P/S ratio 9.03 · Dividend yield 0.4% · Net margin 24.7% · Return on equity 7.3% · Return on assets (EBIT) 7.0% · Operating margin 28.1% · Revenue (TTM) 4.5T KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).
What moves the price
The share trades about 24% below its 52-week high and 21% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −59%, 068270 screens richer than that median.
Fair Value models
Bear 52,383 KRWFair Value 74,519 KRWBull 109,408 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.81/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+17.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.6%
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−1.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−2.3%
Dividend (yield on the price)0.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.6% vs 16%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.39% → 28%
2025 sits 82% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+42.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+16.2%
Yearly sales growth analysts expect, extended to five years.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks
Beats the industry median on 9/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score46 · Above median
Fair Value upside−60% · Below median
Profitability
Return on equity (TTM)7% · Top 25%
Return on assets4% · Top 25%
Net margin (TTM)28% · Top 25%
Operating margin (TTM)28% · Top 25%
Growth and dividend
Revenue growth36% · Top 25%
Dividend yield (TTM)0.4% · Bottom 25%
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/FCF0.1× · Cheapest 25%
PEG0.84× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)29· sector 0
HEALTH (low debt)99· sector 97
DIVIDEND (yield)8· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Celltrion Inc Fair Value". https://www.fairvalue-calculator.com/stock/068270
Frequently asked questions
Is Celltrion Inc (068270) overvalued or undervalued?
As of Sep 18, 2026, our model estimates a fair value of 74,519 KRW versus a price of 181,400 KRW, about −59% upside (overvalued).
What is the fair value of 068270?
Our model-based fair value for Celltrion Inc is 74,519 KRW (as of Sep 18, 2026), built from audited fundamentals. The current price: 181,400 KRW.
What is the quality score of 068270?
Celltrion Inc has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Celltrion Inc (068270)?
Our model-based price target is the fair value of 74,519 KRW (as of Sep 18, 2026) from 26 valuation models. Cautious scenario 52,383 KRW, optimistic scenario 109,408 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Celltrion Inc stock forecast for 2026?
Our models put fair value at 74,519 KRW, about −59% upside versus a price of 181,400 KRW (overvalued). Cautious scenario 52,383 KRW, optimistic scenario 109,408 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Celltrion Inc (068270)?
Celltrion Inc reported trailing-twelve-month revenue of about 4.5T KRW (latest available figure, as of Sep 18, 2026).
Does Celltrion Inc pay a dividend?
Celltrion Inc currently shows a dividend yield of about 0.39% relative to its recent price (as of Sep 18, 2026).
What growth is priced into Celltrion Inc (068270)?
For today's price to be fair in a discounted-cash-flow model, Celltrion Inc would have to grow free cash flow by +42.8 % per year for five years (discount rate 8.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +17.6 % per year. As of Sep 18, 2026.
What discount rate (WACC) does the fair value of 068270 use?
Our models discount Celltrion Inc at 8.4 %: a base by market capitalisation (large), damped by beta 0.35, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Celltrion Inc that is +42.8 % per year a year over ten years, using the same discount rate (8.4 %) and the same formula as our fair value.
How much growth has Celltrion Inc (068270) delivered so far?
Over the past 5 years revenue at Celltrion Inc grew +17.6 % a year. The price currently implies +42.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Celltrion Inc (068270) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Celltrion Inc (+42.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Celltrion Inc (068270)?
The free-cash-flow yield on the price is 0.79 %: that much free cash flow Celltrion Inc produces per unit of market value. When it exceeds the discount rate of our models (8.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Celltrion Inc (068270)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Celltrion Inc it is 74,519 KRW per share (as of Sep 18, 2026), against a price of 181,400 KRW. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Celltrion Inc stock overvalued or undervalued in 2026?
As of Sep 18, 2026, 068270 trades above its calculated fair value: price 181,400 KRW, fair value 74,519 KRW, a gap of about −59% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 068270?
No. The price is what the market pays today (181,400 KRW); the fair value is what the company's own numbers justify (74,519 KRW). For Celltrion Inc the two are 106,881 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Celltrion Inc worth?
The market values Celltrion Inc at about 39.7T KRW (market capitalisation, as of Sep 18, 2026). Per share that is 181,400 KRW; our models calculate a fair value of 74,519 KRW per share.
What do the bullish and bearish scenarios say about 068270?
Our models span a range for Celltrion Inc: cautious scenario 52,383 KRW, base 74,519 KRW, optimistic 109,408 KRW per share (as of Sep 18, 2026, price 181,400 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of 068270?
The PEG ratio of Celltrion Inc is 0.84 (P/E divided by earnings growth, as of Sep 18, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Celltrion Inc (068270)?
Balance-sheet figures for Celltrion Inc (as of Sep 18, 2026): return on equity 7.3%, debt of 0.02 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is 068270 from its 52-week high?
Celltrion Inc trades at 181,400 KRW, about 24% below its 52-week high of 239,048 KRW and 21% above the low of 149,944 KRW (as of Sep 18, 2026). Distance from the high says nothing about value: that is what the fair value of 74,519 KRW is for.
Which stocks are comparable to Celltrion Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Celltrion Inc stock attractive at the current price?
The data as of Sep 18, 2026: price 181,400 KRW, calculated fair value 74,519 KRW (−59%), Quality Score 46/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 068270 calculated?
We run Celltrion Inc through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 74,519 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. Celltrion Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Celltrion Inc (068270)?
The closing price on Sep 21, 2026 was 181,400 KRW. Our model-based fair value is 74,519 KRW, about −59% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Celltrion Inc right now?
The price sits above even our optimistic bull case (109,408 KRW). The favourable scenario is already priced in. Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (52,383 KRW to 109,408 KRW) leaves room in how you read the outcome.
Where does the earnings growth of Celltrion Inc (068270) come from?
Earnings per share at Celltrion Inc grew +12.8 % a year from 2011 to 2022. Broken into its drivers: revenue per share +21.3 %, EBIT margin −5.0 %, tax rate −1.3 %, residual (interest, one-offs) −0.8 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Celltrion Inc
How large is the market capitalisation of Celltrion Inc (068270)?
The market capitalisation of Celltrion Inc is 39.7T KRW (≈ $27.8B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Celltrion Inc (068270)?
The price-to-sales ratio of Celltrion Inc is 9.03 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Celltrion Inc (068270)?
The dividend yield of Celltrion Inc is 0.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Celltrion Inc (068270)?
The net margin of Celltrion Inc is 24.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Celltrion Inc (068270)?
The return on equity (ROE) of Celltrion Inc is 7.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Celltrion Inc (068270)?
On an EBIT basis the return on assets of Celltrion Inc is 7.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Celltrion Inc (068270)?
The operating margin of Celltrion Inc is 28.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Celltrion Inc (068270)?
Revenue at Celltrion Inc is growing +36.0% versus a year earlier (3y avg +22.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Celltrion Inc (068270)?
Earnings per share at Celltrion Inc are growing +224% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Celltrion Inc (068270) carry?
The net debt of Celltrion Inc is 2.6T KRW (fiscal year 2025, ≈ 8.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Celltrion Inc in the live analysis
One click puts Celltrion Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
